Manning Paul B
Director · Candel Therapeutics, Inc.
Every open-market stock purchase Manning Paul B has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.
Where the buys stand today
- VRCAVerrica Pharmaceuticals Inc.
2 purchases totalling $17.5M at an average of $4.24 per share. See all insider buying in VRCA →
Avg price paid$4.24Latest price—Market capUnknown - CADLCandel Therapeutics, Inc.
3 purchases totalling $10.5M at an average of $5.83 per share. See all insider buying in CADL →
Avg price paid$5.83Latest price—Market capUnknown - TSHATaysha Gene Therapies, Inc.
2 purchases totalling $5.1M at an average of $2.43 per share. See all insider buying in TSHA →
Avg price paid$2.43Latest price—Market capUnknown - LQDA+790.0% vs price paidLiquidia Corp
One purchase totalling $3.0M at an average of $8.90 per share; the stock last traded at $79.21. See all insider buying in LQDA →
Avg price paid$8.90Latest price$79.21Market cap$7.0B
Cluster participation
Qualifying buys grouped with other insiders buying the same stock — the pattern this site exists to catch.
All reported buys
| Date | Ticker | Shares | Price | Value | Filing |
|---|---|---|---|---|---|
| Feb 23, 2026 | 550,458 | $5.45 | $3.0M | SEC ↗ | |
| Nov 25, 2025 | VRCAcluster | 1,375,380 | $4.24 | $5.8M | SEC ↗ |
| Nov 25, 2025 | VRCAcluster | 2,750,762 | $4.24 | $11.7M | SEC ↗ |
| May 30, 2025 | 750,000 | $2.75 | $2.1M | SEC ↗ | |
| Dec 16, 2024 | 750,000 | $6.00 | $4.5M | SEC ↗ | |
| Dec 16, 2024 | 500,000 | $6.00 | $3.0M | SEC ↗ | |
| Sep 12, 2024 | LQDAcluster | 337,078 | $8.90 | $3.0M | SEC ↗ |
| Jun 27, 2024 | 1,333,333 | $2.25 | $3.0M | SEC ↗ |
Follow new qualifying clusters involving Manning Paul B or other insiders
Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.
About this data
Figures are parsed from Manning Paul B's Form 4 filings on SEC EDGAR (CIK 1494695) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.